Latest news with #Evolut
Reuters
21-07-2025
- Business
- Reuters
Medtronic wins US appeal to overturn $106.5 mln heart-valve patent verdict
July 18 (Reuters) - A U.S. appeals court on Friday overturned a jury's verdict that medical device maker Medtronic (MDT.N), opens new tab owes competitor Colibri $106.5 million for infringing a patent related to heart valve technology. The U.S. Court of Appeals for the Federal Circuit determined, opens new tab that a California judge should have ruled before the trial that Minneapolis-based Medtronic's devices did not violate Colibri's patent rights. Medtronic said in a statement that the decision "affirms our longstanding position that Colibri's patent infringement claims lacked merit." Spokespeople and an attorney for Colibri did not immediately respond to requests for comment. Colorado-based Colibri alleged in a 2020 lawsuit that Medtronic's Evolut devices for replacing heart valves in heart disease patients infringed a Colibri patent related to deploying artificial heart valves. The patent relates to Colibri's competing heart valve implant system. Colibri said in the lawsuit that company officials shared information about its patented technology with Medtronic in 2014, before Medtronic introduced its Evolut system. A jury found in 2023 that Medtronic's devices infringed Colibri's patent. A three-judge Federal Circuit panel overturned the verdict on Friday, agreeing with Medtronic that the district court judge should have ruled for the company before the case went to a jury trial. The case is Colibri Heart Valve LLC v. Medtronic CoreValve LLC, U.S. Court of Appeals for the Federal Circuit, No. 23-2153. For Colibri: Jeffrey Lamken of MoloLamken For Medtronic: Greg Castanias of Jones Day Read more: Medtronic hit with $106.5 mln U.S. verdict in heart-valve patent case
Yahoo
31-05-2025
- Business
- Yahoo
CCC Intelligent Solutions Holdings Inc. (CCCS): A Bull Case Theory
We came across a bullish thesis on CCC Intelligent Solutions Holdings Inc. (CCCS) on R. Dennis's Substack. In this article, we will summarize the bulls' thesis on CCCS. CCC Intelligent Solutions Holdings Inc. (CCCS)'s share was trading at $8.47 as of 23rd May. CCCS's trailing and forward P/E were 847 and 20.66 respectively according to Yahoo Finance. Highlighting the company's sector and industry, a technician working on a complex SaaS in a technology lab. CCC Intelligent Solutions Holdings Inc. (CCCS) demonstrates solid financial health with consistent revenue growth and strong free cash flow, supported by its asset-light SaaS business model. Capital expenditures remain modest relative to revenue, focusing on technology infrastructure and software development, essential for sustaining innovation and growth. The company's free cash flow has shown a steady increase, providing financial flexibility for investments, debt management, and shareholder returns. While GAAP profitability has been volatile due to non-cash charges and impairments, adjusted profitability metrics highlight the company's underlying operational strength. Leverage levels are moderate but warrant monitoring given recent acquisitions and share repurchases. CCCS benefits from a dominant market position in North American auto physical damage claims technology, backed by a robust multi-sided network, high customer retention, and extensive proprietary data fueling AI innovation. The strategic acquisition of EvolutionIQ diversifies its product offerings into casualty claims, expanding growth opportunities. Management emphasizes navigating current macroeconomic headwinds, including declining claim volumes, while focusing on operational efficiency and AI-driven solutions to maintain competitive advantage. Valuation metrics indicate a reasonable market pricing with a projected 10-12% five-year internal rate of return based on discounted cash flow analysis. Risks include competition, integration challenges, cybersecurity, and regulatory changes, but the company's strong market leadership, recurring revenue model, and continuous investment in AI position it well for long-term growth. Overall, CCCS's outlook is positive, driven by ongoing digitization in the insurance industry, expanding AI capabilities, and growth in adjacent markets, despite near-term uncertainties from economic and industry-specific factors. For a deeper look into another technology stock, be sure to check out our article on Salesforce, Inc. (CRM), wherein we summarized a bullish thesis by Quality Equities on Substack. CCC Intelligent Solutions Holdings Inc. (CCCS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 37 hedge fund portfolios held CCCS at the end of the first quarter which was 26 in the previous quarter. While we acknowledge the risk and potential of CCCS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CCCS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-05-2025
- Business
- Yahoo
CCC Intelligent Solutions Holdings Inc. (CCCS): A Bull Case Theory
We came across a bullish thesis on CCC Intelligent Solutions Holdings Inc. (CCCS) on R. Dennis's Substack. In this article, we will summarize the bulls' thesis on CCCS. CCC Intelligent Solutions Holdings Inc. (CCCS)'s share was trading at $8.47 as of 23rd May. CCCS's trailing and forward P/E were 847 and 20.66 respectively according to Yahoo Finance. Highlighting the company's sector and industry, a technician working on a complex SaaS in a technology lab. CCC Intelligent Solutions Holdings Inc. (CCCS) demonstrates solid financial health with consistent revenue growth and strong free cash flow, supported by its asset-light SaaS business model. Capital expenditures remain modest relative to revenue, focusing on technology infrastructure and software development, essential for sustaining innovation and growth. The company's free cash flow has shown a steady increase, providing financial flexibility for investments, debt management, and shareholder returns. While GAAP profitability has been volatile due to non-cash charges and impairments, adjusted profitability metrics highlight the company's underlying operational strength. Leverage levels are moderate but warrant monitoring given recent acquisitions and share repurchases. CCCS benefits from a dominant market position in North American auto physical damage claims technology, backed by a robust multi-sided network, high customer retention, and extensive proprietary data fueling AI innovation. The strategic acquisition of EvolutionIQ diversifies its product offerings into casualty claims, expanding growth opportunities. Management emphasizes navigating current macroeconomic headwinds, including declining claim volumes, while focusing on operational efficiency and AI-driven solutions to maintain competitive advantage. Valuation metrics indicate a reasonable market pricing with a projected 10-12% five-year internal rate of return based on discounted cash flow analysis. Risks include competition, integration challenges, cybersecurity, and regulatory changes, but the company's strong market leadership, recurring revenue model, and continuous investment in AI position it well for long-term growth. Overall, CCCS's outlook is positive, driven by ongoing digitization in the insurance industry, expanding AI capabilities, and growth in adjacent markets, despite near-term uncertainties from economic and industry-specific factors. For a deeper look into another technology stock, be sure to check out our article on Salesforce, Inc. (CRM), wherein we summarized a bullish thesis by Quality Equities on Substack. CCC Intelligent Solutions Holdings Inc. (CCCS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 37 hedge fund portfolios held CCCS at the end of the first quarter which was 26 in the previous quarter. While we acknowledge the risk and potential of CCCS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CCCS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
23-05-2025
- Health
- Yahoo
Edwards' study demonstrates value in early aortic stenosis intervention
New research by Edwards Lifesciences has demonstrated that early intervention for severe aortic stenosis (AS) before symptoms develop improves patient outcomes and reduces the economic and resource burden on healthcare systems. Edwards' real-world study of more than 24,000 patients with severe AS demonstrated that prompt intervention resulted in an average of 2.2 fewer days spent in hospitals during patients' treatment, 80% fewer heart failure hospitalisations one year after treatment, and cost reductions of $36,000 per patient at the one-year point. The study results were presented as a late-breaking clinical trial at EuroPCR 2025, taking place in Paris, France, between 20 and 23 May. Larry Wood, Edwards' corporate vice president and transcatheter aortic valve replacement (TAVR) and surgical group president, said: 'We are dedicated to advancing robust evidence to help improve outcomes for patients with severe AS. 'These latest findings underscore the importance of early referral to a heart valve team and timely care of patients with severe AS, reducing the economic and resource burden for hospitals.' It is no surprise that Edwards is shining a light on early AS intervention. The medtech giant recently received approval from the US Food and Drug Administration (FDA) on an indication expansion for its SAPIEN 3 TAVR platform in the treatment of patients with asymptomatic severe AS. The approval was supported by data from Edwards' EARLY TAVR trial (NCT03042104). The results demonstrated that asymptomatic severe AS patients randomised to the company's TAVR experienced superior outcomes versus guideline-recommended clinical surveillance (watchful waiting). At a median follow-up of 3.8 years, the data showed that 26.8% of the 455 patients in the trial's TAVR arm experienced death, stroke or unplanned cardiovascular hospitalisation versus 45.3% of the 446 patients in the clinical surveillance arm. According to GlobalData analysis, the global TAVR market is forecast to reach a valuation of around $13.7bn by 2033, up from $6.16bn in 2023. GlobalData's US Healthcare Facility Invoicing Database indicates that Edwards Lifesciences is currently the TAVR market leader, holding more than a 60% share of the US TAVR market. But change may be afoot. Medtronic recently released two-year results from a clinical trial comparing its Evolut system to Edwards' SAPIEN, with the data showing that the Evolut system led to significantly less bioprosthetic valve dysfunction, five times less prosthetic valve thrombosis, and nine times less haemodynamic structural valve dysfunction than the SAPIEN system. According to GlobalData analysis, the Evolut system could become the preferred option among healthcare professionals for patients with symptomatic severe AS and small aortic annulus categories, as evaluated in the trial. "Edwards' study demonstrates value in early aortic stenosis intervention" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
23-05-2025
- Health
- Yahoo
Edwards' study demonstrates value in early aortic stenosis intervention
New research by Edwards Lifesciences has demonstrated that early intervention for severe aortic stenosis (AS) before symptoms develop improves patient outcomes and reduces the economic and resource burden on healthcare systems. Edwards' real-world study of more than 24,000 patients with severe AS demonstrated that prompt intervention resulted in an average of 2.2 fewer days spent in hospitals during patients' treatment, 80% fewer heart failure hospitalisations one year after treatment, and cost reductions of $36,000 per patient at the one-year point. The study results were presented as a late-breaking clinical trial at EuroPCR 2025, taking place in Paris, France, between 20 and 23 May. Larry Wood, Edwards' corporate vice president and transcatheter aortic valve replacement (TAVR) and surgical group president, said: 'We are dedicated to advancing robust evidence to help improve outcomes for patients with severe AS. 'These latest findings underscore the importance of early referral to a heart valve team and timely care of patients with severe AS, reducing the economic and resource burden for hospitals.' It is no surprise that Edwards is shining a light on early AS intervention. The medtech giant recently received approval from the US Food and Drug Administration (FDA) on an indication expansion for its SAPIEN 3 TAVR platform in the treatment of patients with asymptomatic severe AS. The approval was supported by data from Edwards' EARLY TAVR trial (NCT03042104). The results demonstrated that asymptomatic severe AS patients randomised to the company's TAVR experienced superior outcomes versus guideline-recommended clinical surveillance (watchful waiting). At a median follow-up of 3.8 years, the data showed that 26.8% of the 455 patients in the trial's TAVR arm experienced death, stroke or unplanned cardiovascular hospitalisation versus 45.3% of the 446 patients in the clinical surveillance arm. According to GlobalData analysis, the global TAVR market is forecast to reach a valuation of around $13.7bn by 2033, up from $6.16bn in 2023. GlobalData's US Healthcare Facility Invoicing Database indicates that Edwards Lifesciences is currently the TAVR market leader, holding more than a 60% share of the US TAVR market. But change may be afoot. Medtronic recently released two-year results from a clinical trial comparing its Evolut system to Edwards' SAPIEN, with the data showing that the Evolut system led to significantly less bioprosthetic valve dysfunction, five times less prosthetic valve thrombosis, and nine times less haemodynamic structural valve dysfunction than the SAPIEN system. According to GlobalData analysis, the Evolut system could become the preferred option among healthcare professionals for patients with symptomatic severe AS and small aortic annulus categories, as evaluated in the trial. "Edwards' study demonstrates value in early aortic stenosis intervention" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
